Press Release Archive - R&D News

R&D News

02.23.2012
Forest and Almirall Announce Positive FDA Advisory Committee’s Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
10.27.2011
Ironwood and Forest to Present Linaclotide Results from Phase 2B and Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation
10.24.2011
Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review
10.05.2011
Forest Laboratories, Inc. and Gedeon Richter Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
08.09.2011
Ironwood and Forest Announce Submission of New Drug Application for Linaclotide for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation
07.18.2011
Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Positive Phase III Results with Levomilnacipran in Patients with Major Depressive Disorder
06.30.2011
Forest and Almirall Announce Submission of New Drug Application for Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
05.09.2011
Forest and Almirall to Present Data from Phase III Studies of Aclidinium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
05.04.2011
Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation
02.28.2011
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder